MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- GLAXOSMITHKLINE CONSUMER HEALTHCARE LTD. (beverages, food & tobacco)
- GLAXOSMITHKLINE CONSUMER HEALTHCARE LTD. Financial Data
GSK Consumer Fact Sheet 
(SBCH)
Here is the latest financial fact sheet of GSK Consumer. For more details, see the GSK Consumer quarterly results and GSK Consumer share price and chart.
GSK CONSUMER Price History
| % ch | % | -0.8 |
| No. of shares | m | 42.06 |
| % ch week | % | 3.5 |
| % ch 1-mth | % | 3.3 |
| % ch 12-mth | % | 25.0 |
| 52 week H/L | Rs | 7,934.9/5,883.6 |
GSK CONSUMER Financials
| No. of Mths Year Ending |
15 Mar-14 |
12 Mar-15 |
12 Mar-16 |
12 Mar-17 |
12 Mar-18 |
5-Yr Chart Click to enlarge
|
|---|
| GSK CONSUMER EQUITY SHARE DATA | |||||||
|---|---|---|---|---|---|---|---|
| High | Rs | 5,847 | 6,354 | 6,771 | 6,551 | 6,793 | |
| Low | Rs | 3,668 | 5,730 | 5,448 | 4,921 | 4,919 | |
| Sales per share (Unadj.) | Rs | 1,157.5 | 1,024.2 | 983.4 | 948.9 | 1,026.3 | |
| Earnings per share (Unadj.) | Rs | 160.4 | 138.8 | 163.4 | 156.1 | 166.5 | |
| Diluted earnings per share | Rs | 160.4 | 138.8 | 163.4 | 156.1 | 166.5 | |
| Cash flow per share (Unadj.) | Rs | 175.3 | 153.5 | 177.1 | 171.4 | 181.8 | |
| Dividends per share (Unadj.) | Rs | 45.00 | 55.00 | 70.00 | 70.00 | 75.00 | |
| Adj. dividends per share | Rs | 45.00 | 55.00 | 70.00 | 70.00 | 75.00 | |
| Dividend yield (eoy) | % | 0.9 | 0.9 | 1.1 | 1.2 | 1.3 | |
| Book value per share (Unadj.) | Rs | 431.0 | 569.1 | 665.4 | 742.4 | 828.6 | |
| Adj. book value per share | Rs | 431.0 | 569.1 | 665.4 | 742.4 | 828.6 | |
| Shares outstanding (eoy) | m | 42.06 | 42.06 | 42.06 | 42.06 | 42.06 | |
| Bonus/Rights/Conversions | - | - | - | - | - | ||
| Price / Sales ratio | x | 4.1 | 5.9 | 6.2 | 6.0 | 5.7 | |
| Avg P/E ratio | x | 29.7 | 43.5 | 37.4 | 36.7 | 35.2 | |
| P/CF ratio (eoy) | x | 27.1 | 39.4 | 34.5 | 33.5 | 32.2 | |
| Price / Book Value ratio | x | 11.0 | 10.6 | 9.2 | 7.7 | 7.1 | |
| Dividend payout | % | 28.1 | 39.6 | 42.8 | 44.8 | 45.1 | |
| Avg Mkt Cap | Rs m | 200,117 | 254,112 | 256,959 | 241,265 | 246,284 | |
| No. of employees | `000 | 3.5 | 3.5 | 3.7 | 3.8 | 4.0 | |
| Total wages/salary | Rs m | 4,701 | 4,313 | 5,050 | 4,509 | 5,277 | |
| Avg. sales/employee | Rs Th | 13,902.3 | 12,213.2 | 11,086.2 | 10,484.1 | 10,837.3 | |
| Avg. wages/employee | Rs Th | 1,342.3 | 1,222.8 | 1,353.5 | 1,184.3 | 1,325.0 | |
| Avg. net profit/employee | Rs Th | 1,926.7 | 1,654.7 | 1,842.1 | 1,724.9 | 1,757.7 | |
| GSK CONSUMER INCOME DATA | |||||||
|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 48,686 | 43,076 | 41,363 | 39,913 | 43,165 | |
| Other income | Rs m | 2,069 | 2,219 | 2,775 | 2,391 | 2,574 | |
| Total revenues | Rs m | 50,755 | 45,295 | 44,138 | 42,303 | 45,739 | |
| Gross profit | Rs m | 8,728 | 7,368 | 8,382 | 8,383 | 8,834 | |
| Depreciation | Rs m | 626 | 621 | 574 | 642 | 644 | |
| Interest | Rs m | 11 | 74 | 23 | 28 | 20 | |
| Profit before tax | Rs m | 10,161 | 8,891 | 10,560 | 10,104 | 10,744 | |
| Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
| Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | 0 | |
| Tax | Rs m | 3,413 | 3,055 | 3,687 | 3,537 | 3,743 | |
| Profit after tax | Rs m | 6,747 | 5,836 | 6,873 | 6,567 | 7,001 | |
| Gross profit margin | % | 17.9 | 17.1 | 20.3 | 21.0 | 20.5 | |
| Effective tax rate | % | 33.6 | 34.4 | 34.9 | 35.0 | 34.8 | |
| Net profit margin | % | 13.9 | 13.5 | 16.6 | 16.5 | 16.2 | |
| GSK CONSUMER BALANCE SHEET DATA | |||||||
|---|---|---|---|---|---|---|---|
| Current assets | Rs m | 27,539 | 33,063 | 37,576 | 41,391 | 45,620 | |
| Current liabilities | Rs m | 14,766 | 14,010 | 14,567 | 15,956 | 17,426 | |
| Net working cap to sales | % | 26.2 | 44.2 | 55.6 | 63.7 | 65.3 | |
| Current ratio | x | 1.9 | 2.4 | 2.6 | 2.6 | 2.6 | |
| Inventory Days | Days | 31 | 40 | 41 | 42 | 35 | |
| Debtors Days | Days | 22 | 27 | 31 | 29 | 24 | |
| Net fixed assets | Rs m | 3,784 | 5,362 | 5,320 | 5,362 | 5,138 | |
| Share capital | Rs m | 421 | 421 | 421 | 421 | 421 | |
| "Free" reserves | Rs m | 17,708 | 23,517 | 27,567 | 30,806 | 34,431 | |
| Net worth | Rs m | 18,129 | 23,937 | 27,987 | 31,227 | 34,851 | |
| Long term debt | Rs m | 0 | 0 | 0 | 0 | 0 | |
| Total assets | Rs m | 34,115 | 40,218 | 44,953 | 49,547 | 54,127 | |
| Interest coverage | x | 968.7 | 121.0 | 464.1 | 364.5 | 530.2 | |
| Debt to equity ratio | x | 0 | 0 | 0 | 0 | 0 | |
| Sales to assets ratio | x | 1.4 | 1.1 | 0.9 | 0.8 | 0.8 | |
| Return on assets | % | 19.8 | 14.7 | 15.3 | 13.3 | 13.0 | |
| Return on equity | % | 37.2 | 24.4 | 24.6 | 21.0 | 20.1 | |
| Return on capital | % | 56.1 | 37.5 | 37.8 | 32.4 | 30.9 | |
| Exports to sales | % | 6.5 | 5.3 | 5.3 | 0 | 0 | |
| Imports to sales | % | 0.8 | 1.1 | 0.4 | 0 | 0 | |
| Exports (fob) | Rs m | 3,161 | 2,275 | 2,211 | 0 | 0 | |
| Imports (cif) | Rs m | 397 | 491 | 168 | 0 | 0 | |
| Fx inflow | Rs m | 3,255 | 2,353 | 2,816 | 2,591 | 3,014 | |
| Fx outflow | Rs m | 2,045 | 672 | 261 | 282 | 186 | |
| Net fx | Rs m | 1,210 | 1,681 | 2,555 | 2,310 | 2,828 | |
| GSK CONSUMER CASH FLOW | |||||||
|---|---|---|---|---|---|---|---|
| From Operations | Rs m | 6,445 | 6,115 | 5,735 | 6,030 | 7,230 | |
| From Investments | Rs m | -2,714 | 3,307 | -1,516 | -6,024 | -4,465 | |
| From Financial Activity | Rs m | -2,227 | -2,222 | -2,856 | -3,615 | -3,634 | |
| Net Cashflow | Rs m | 1,504 | 7,200 | 1,363 | -3,609 | -868 | |
Share Holding
|
Company Information
|
|||||||||||||||||||||||||||||||||||||||||
| CHM: Simon J. Scarff | COMP SEC: Sonali Khanna | YEAR OF INC: 1958 | BSE CODE: 500676 | FV (Rs): 10 | DIV YIELD (%): 1.0 |
More Beverages, Food & Tobacco Company Fact Sheets: ZYDUS WELLNESS VADILAL INDUSTRIES TATA COFFEE BRITANNIA UNITED SPIRITS
Compare GSK CONSUMER With: ZYDUS WELLNESS VADILAL INDUSTRIES TATA COFFEE BRITANNIA UNITED SPIRITS
Compare GSK CONSUMER With: COCA COLA (US) NESTLE (Switz.) TIGER BRANDS (S. Africa) AVI LTD. (S. Africa)
|
| |
Today's Market
Sensex Ends 382 Points Lower; Auto and Telecom Stocks Witness Selling(Closing)
India share markets witnessed huge selling pressure during closing hours and ended their trading session deep in the red.
Views on news
GSK CONSUMER Announces Quarterly Results (4QFY19); Net Profit Up 34.9% (Quarterly Result Update)
May 13, 2019 | Updated on May 13, 2019For the quarter ended March 2019, GSK CONSUMER has posted a net profit of Rs 3 bn (up 34.9% YoY). Sales on the other hand came in at Rs 13 bn (up 9.0% YoY). Read on for a complete analysis of GSK CONSUMER's quarterly results.
GSK CONSUMER Announces Quarterly Results (3QFY19); Net Profit Up 35.1% (Quarterly Result Update)
Feb 18, 2019 | Updated on Feb 18, 2019For the quarter ended December 2018, GSK CONSUMER has posted a net profit of Rs 2 bn (up 35.1% YoY). Sales on the other hand came in at Rs 11 bn (up 7.9% YoY). Read on for a complete analysis of GSK CONSUMER's quarterly results.
GSK Consumer: On the Recovery Path (Quarterly Results Update - Detailed)
Jun 20, 2017While GSK consumer reported muted revenue growth, volumes are seen to be recovering.
Prataap Snacks Ltd. (IPO)
Sep 21, 2017Is the Prataap Snacks IPO worth your attention?
Apex frozen food Ltd. (IPO)
Aug 21, 2017Should you subscribe to the IPO of Apex Frozen Foods Ltd?
More Views on NewsMost Popular
3 Indian Stocks Replicating Amazon's Successful Strategy(The 5 Minute Wrapup)
May 10, 2019The one critical element that has made Amazon a force to reckon with...
My Top 7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)
May 16, 2019Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.
3 Stocks to Bet on to Become a 'Dividend Millionaire'(Profit Hunter)
May 14, 2019As markets continue to rattle amid earning season, upcoming elections, volatile crude price and US China trade war, it's a great idea to add some stability to your portfolio by adding dividend stocks.
A Simple Checklist for Picking Great Dividend Stocks(Profit Hunter)
May 9, 2019A filtered, neat list of high-dividend stocks with all this dirty work already done for you.
The Bitter Pill that Will Lay the Foundation for Sensex 100,000(The 5 Minute Wrapup)
May 14, 2019These companies will help the Sensex more than double from current levels.
More|
| |
TRACK GSK CONSUMER
- Track your investment in GSK CONSUMER with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON GSK CONSUMER
GSK CONSUMER - RAJ OIL MILLS COMPARISON
COMPARE GSK CONSUMER WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.